Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
American Journal of Obstetrics and Gynecology|August 3, 2010
The maternal body mass index: a strong association with delivery routeMichelle A Kominiarek, Paul Vanveldhuisen, Judith Hibbard, et al.JAMA|July 29, 2010
Respiratory morbidity in late preterm births, Judith U Hibbard, Isabelle Wilkins, et al.Obstetrics and Gynecology|February 24, 2011
Characteristics associated with severe perineal and cervical lacerations during vaginal deliveryHelain J Landy, S Katherine Laughon, Jennifer L Bailit, et al.Biorxiv : the Preprint Server for Biology|February 3, 2025
Neoplastic immune mimicry potentiates breast tumor progressionEric B Berens, Sokchea Khou, Elaine Huang, et al.Cancer Research|October 23, 2025
Neoplastic Immune Mimicry Potentiates Breast Tumor ProgressionEric B Berens, Sokchea Khou, Elaine T Huang, et al.Blood|March 17, 2011
Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLCLaurent Sutton, Sylvie Chevret, Olivier Tournilhac, et al.Blood|January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapyLaetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA StudyGuillaume Cartron, Emmanuel Bachy, Hervé Tilly, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2017
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneCatherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, et al.International Journal of Radiation Oncology, Biology, Physics|December 13, 2017
Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized TrialJosé Thomas, Christophe Fermé, Evert M Noordijk, et al.Pageof 7